FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377013992> ?p ?o ?g. }

• W4377013992 endingPage "e93" @default.
• W4377013992 startingPage "e83" @default.
• W4377013992 abstract "Despite recent advances, it is not clear whether the various genes/genetic variants related to amyotrophic lateral sclerosis (ALS) interact in modifying patients' phenotype. The aim of this study was to determine whether the copresence of genetic variants related to ALS has interactive effects on the course of the disease.The study population includes 1,245 patients with ALS identified through the Piemonte Register for ALS between 2007 and 2016 and not carrying superoxide dismutase type 1, TAR DNA binding protein, and fused in sarcoma pathogenic variants. Controls were 766 Italian participants age-matched, sex-matched, and geographically matched to cases. We considered Unc-13 homolog A (UNC13A) (rs12608932), calmodulin binding transcription activator 1 (CAMTA1) (rs2412208), solute carrier family 11 member 2 (SLC11A2) (rs407135), and zinc finger protein 512B (ZNF512B) (rs2275294) variants, as well as ataxin-2 (ATXN2) polyQ intermediate repeats (≥31) and chromosome 9 open reading frame 72 (C9orf72) GGGGCC intronic expansions (≥30).The median survival time of the whole cohort was 2.67 years (interquartile range [IQR] 1.67-5.25). In univariate analysis, only C9orf72 (2.51 years, IQR 1.74-3.82; p = 0.016), ATXN2 (1.82 years, IQR 1.08-2.33; p < 0.001), and UNC13AC/C (2.3 years, IQR 1.3-3.9; p < 0.001) significantly reduced survival. In Cox multivariable analysis, CAMTA1 also emerged to be independently related to survival (hazard ratio 1.13, 95% CI 1.001-1.30, p = 0.048). The copresence of 2 detrimental alleles/expansions was correlated with shorter survival. In particular, the median survival of patients with CAMTA1G/G+G/T and UNC13AC/C alleles was 1.67 years (1.16-3.08) compared with 2.75 years (1.67-5.26) of the patients not carrying these variants (p < 0.001); the survival of patients with CAMTA1G/G+G/T alleles and ATXN2≥31 intermediate polyQ repeats was 1.75 years (0.84-2.18) (p < 0.001); the survival of patients with ATXN2≥31 polyQ repeats and UNC13AC/C allele was 1.33 years (0.84-1.75) (p < 0.001); the survival of patients with C9ORF72≥30 and UNC13AC/C allele was 1.66 years (1.41-2.16). Each pair of detrimental alleles/expansions was associated to specific clinical phenotypes.We showed that gene variants acting as modifiers of ALS survival or phenotype can act on their own or in unison. Overall, 54% of patients carried at least 1 detrimental common variant or repeat expansion, emphasizing the clinical impact of our findings. In addition, the identification of the interactive effects of modifier genes represents a crucial clue for explaining ALS clinical heterogeneity and should be considered when designing and interpreting clinical trials results." @default.
• W4377013992 created "2023-05-19" @default.
• W4377013992 creator A5009010906 @default.
• W4377013992 creator A5010130098 @default.
• W4377013992 creator A5011286489 @default.
• W4377013992 creator A5013689467 @default.
• W4377013992 creator A5018020880 @default.
• W4377013992 creator A5018964271 @default.
• W4377013992 creator A5022850557 @default.
• W4377013992 creator A5030771748 @default.
• W4377013992 creator A5035072440 @default.
• W4377013992 creator A5049549975 @default.
• W4377013992 creator A5050206170 @default.
• W4377013992 creator A5052801313 @default.
• W4377013992 creator A5062052643 @default.
• W4377013992 creator A5063280743 @default.
• W4377013992 creator A5064293919 @default.
• W4377013992 creator A5066369462 @default.
• W4377013992 creator A5066713645 @default.
• W4377013992 creator A5076109679 @default.
• W4377013992 creator A5078664493 @default.
• W4377013992 creator A5082340666 @default.
• W4377013992 creator A5090628289 @default.
• W4377013992 date "2023-07-04" @default.
• W4377013992 modified "2023-10-02" @default.
• W4377013992 title "Association of Copresence of Pathogenic Variants Related to Amyotrophic Lateral Sclerosis and Prognosis" @default.
• W4377013992 cites W2005928129 @default.
• W4377013992 cites W2027552410 @default.
• W4377013992 cites W2033370021 @default.
• W4377013992 cites W2046195905 @default.
• W4377013992 cites W2054960767 @default.
• W4377013992 cites W2109274553 @default.
• W4377013992 cites W2113792524 @default.
• W4377013992 cites W2126602794 @default.
• W4377013992 cites W2161938104 @default.
• W4377013992 cites W2200183975 @default.
• W4377013992 cites W2262519334 @default.
• W4377013992 cites W2415678243 @default.
• W4377013992 cites W2491827732 @default.
• W4377013992 cites W2562172900 @default.
• W4377013992 cites W2735544048 @default.
• W4377013992 cites W2761013105 @default.
• W4377013992 cites W2801181825 @default.
• W4377013992 cites W2898283729 @default.
• W4377013992 cites W2913418608 @default.
• W4377013992 cites W2998363674 @default.
• W4377013992 cites W3093992739 @default.
• W4377013992 cites W3099022480 @default.
• W4377013992 cites W3117204693 @default.
• W4377013992 cites W3125845140 @default.
• W4377013992 cites W3128153416 @default.
• W4377013992 cites W4200193100 @default.
• W4377013992 cites W4206363717 @default.
• W4377013992 cites W4210784246 @default.
• W4377013992 cites W4213435307 @default.
• W4377013992 cites W4213441627 @default.
• W4377013992 cites W4220833172 @default.
• W4377013992 cites W4226322307 @default.
• W4377013992 cites W4250529948 @default.
• W4377013992 cites W4293253492 @default.
• W4377013992 doi "https://doi.org/10.1212/wnl.0000000000207367" @default.
• W4377013992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37202167" @default.
• W4377013992 hasPublicationYear "2023" @default.
• W4377013992 type Work @default.
• W4377013992 citedByCount "0" @default.
• W4377013992 crossrefType "journal-article" @default.
• W4377013992 hasAuthorship W4377013992A5009010906 @default.
• W4377013992 hasAuthorship W4377013992A5010130098 @default.
• W4377013992 hasAuthorship W4377013992A5011286489 @default.
• W4377013992 hasAuthorship W4377013992A5013689467 @default.
• W4377013992 hasAuthorship W4377013992A5018020880 @default.
• W4377013992 hasAuthorship W4377013992A5018964271 @default.
• W4377013992 hasAuthorship W4377013992A5022850557 @default.
• W4377013992 hasAuthorship W4377013992A5030771748 @default.
• W4377013992 hasAuthorship W4377013992A5035072440 @default.
• W4377013992 hasAuthorship W4377013992A5049549975 @default.
• W4377013992 hasAuthorship W4377013992A5050206170 @default.
• W4377013992 hasAuthorship W4377013992A5052801313 @default.
• W4377013992 hasAuthorship W4377013992A5062052643 @default.
• W4377013992 hasAuthorship W4377013992A5063280743 @default.
• W4377013992 hasAuthorship W4377013992A5064293919 @default.
• W4377013992 hasAuthorship W4377013992A5066369462 @default.
• W4377013992 hasAuthorship W4377013992A5066713645 @default.
• W4377013992 hasAuthorship W4377013992A5076109679 @default.
• W4377013992 hasAuthorship W4377013992A5078664493 @default.
• W4377013992 hasAuthorship W4377013992A5082340666 @default.
• W4377013992 hasAuthorship W4377013992A5090628289 @default.
• W4377013992 hasBestOaLocation W43770139921 @default.
• W4377013992 hasConcept C104317684 @default.
• W4377013992 hasConcept C119060515 @default.
• W4377013992 hasConcept C126322002 @default.
• W4377013992 hasConcept C143998085 @default.
• W4377013992 hasConcept C166252455 @default.
• W4377013992 hasConcept C180754005 @default.
• W4377013992 hasConcept C207103383 @default.
• W4377013992 hasConcept C2777898937 @default.
• W4377013992 hasConcept C2779134260 @default.
• W4377013992 hasConcept C2780596555 @default.

• next